

NEWS RELEASE



## **UROPLASTY INTRODUCES NEW ENDOSCOPIC NEEDLE FOR URINARY INCONTINENCE PROCEDURES**

**MINNEAPOLIS, MN, March 10, 2010** – Uroplasty, Inc. (NYSE: Amex UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the introduction of a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique®. Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. This permanent, nonresorbable material is injected into the tissues surrounding the urethra to help improve urethral closure to enhance bladder control.

The newly introduced low-profile MRN-420 needle is designed to be compatible with most adult cystoscopes, instruments used to visually examine the bladder, and to perform urologic procedures. In response to customer suggestions, this needle design project was undertaken in an ongoing effort to improve procedure ease and to allow surgeons to use their cystoscope of choice. The enhanced needle flexibility provides easier handling while the smaller needle tip helps to control the precise flow and amount of product injected.

“Durability of Urethral Bulking Injection for Female Stress Urinary Incontinence: 2-Year Results of a Multicenter Study” will appear in the April 2010 print edition (e-published on February 22, 2010) of *The Journal of Urology*®. “With the publication of this important clinical study, combined with the introduction of the lower-profile needle, Uroplasty believes that the Macroplastique sales momentum we are already experiencing will continue,” said Uroplasty Chief Executive Officer and President David Kaysen. “The new, smaller diameter endoscopic needle will increase our access to more urologists and urogynecologists who can now use Macroplastique with their current cystoscope. We saw U.S. Macroplastique sales more than double in the last fiscal year and we anticipate continued strong interest with associated sales growth,” concluded Mr. Kaysen.

### **About Uroplasty, Inc.**

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization

of our Urgent<sup>®</sup> PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique<sup>®</sup>, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at <http://uroplasty.com>.

For complete information regarding Macroplastique indications, contraindications, warnings, precautions, instructions for use, storage, adverse reactions and disclaimer of warranties, please refer to the Instructions for Use brochure available at the Uroplasty website.

### **Forward-Looking Information**

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, our ability to continue to grow the market share of Macroplastique is subject to a number risks, including the risk that superior technology is developed for the control of adult female urinary incontinency, that competitors with superior personnel and financial resources are able to better market their products, or that physicians select other products because of delivery methods or otherwise.

<b>For Further Information:</b> <u>Uroplasty, Inc.</u> David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140	<u>EVC Group</u> Doug Sherk (Investors), 415.896.6820 Chris Gale (Media), 646.201.5431
---	--

###